MEDICINOVA INCMNOV
時価総額
$7553.1万
PER
バイオ医薬の新興企業。MN-166（ibudilast）とMN-001（tipelukast）による神経疾患・NAFLD向け開発を展開。2024年12月期の純損失は1,100万ドル、累積欠損426.8百万ドル。米国と日本を中心に展開。
| 2011年 12月31日 | 2012年 12月31日 | 2013年 12月31日 | 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | 2024年 12月31日 | |
| Net loss | - | - | - | - | - | - | - | -14,675,087 | -12,941,658 | -13,853,897 | -10,134,252 | -14,069,083 | -8,571,516 | -11,049,549 |
| Non-cash stock-based compensation | 50 | 50 | 1 | 2 | 2 | 4 | 4 | 6 | 4 | 3 | 2 | 642,522 | 710,710 | 1 |
| Depreciation and amortization | 2 | 2 | 100,487 | 40,186 | 26,704 | 14,127 | 28,098 | 25,881 | 23,944 | 21,342 | 26,149 | 17,707 | 20,295 | 21,077 |
| Non-cash interest on investments | - | - | - | - | - | - | - | - | - | - | - | 154,003 | 346,390 | - |
| Loss on disposal of investments | - | - | - | - | - | - | - | - | - | - | - | -122,475 | -448,903 | - |
| (Gain) loss on disposal of property and equipment | - | - | - | - | - | - | - | - | - | - | -286 | - | -472 | 198 |
| Change in carrying amount of right-of-use asset | - | - | - | - | - | - | - | - | - | - | - | 194,719 | 194,502 | 173,522 |
| Prepaid expenses and other assets | 577,591 | 310,664 | 1 | -1,186,352 | -284,538 | -175,495 | - | - | - | - | -50,319 | -150,605 | -287,628 | 491,005 |
| Accounts payable, accrued liabilities and other liabilities | - | - | - | - | - | - | - | - | - | - | - | 329,010 | 19,238 | -312,347 |
| Operating lease liabilities | - | - | - | - | - | - | - | - | - | - | -231,735 | -145,515 | -194,880 | -176,204 |
| Net cash used in operating activities | -13,308,652 | -11,864,438 | -10,646,456 | - | - | - | - | -9,114,121 | -9,124,987 | -10,826,362 | -9,381,605 | -12,911,563 | -7,431,038 | -10,642,964 |
| Purchases of investments | - | - | - | - | - | - | - | - | - | - | - | 60 | - | - |
| Proceeds from disposal of investments | - | - | - | - | - | - | - | - | - | - | - | 20 | 40 | - |
| Proceeds from sale of property and equipment | 256,845 | 256,845 | 4,800 | - | - | - | - | - | - | - | - | - | - | 198 |
| Acquisitions of property and equipment | 2 | 2 | 41,554 | 3,523 | 2,320 | 84,483 | - | 10,200 | 11,272 | 36,492 | 28,732 | 5,010 | 21,299 | 895 |
| Net cash provided by (used in) investing activities | -6,085 | -763,378 | -36,754 | - | - | - | - | 626,324 | -11,272 | -36,492 | -28,732 | -40,005,010 | 40 | -697 |
| Proceeds From Issuance Of Common Stock Exercise Of Common Stock Options | - | - | - | - | - | - | - | - | - | 7 | 21 | 7,920 | - | - |
| Net cash provided by financing activities | 217 | 219 | 13 | - | - | - | - | 43 | 11 | 7 | 21 | 7,920 | - | - |
| Effect of exchange rate changes on cash and cash equivalents | - | - | - | - | - | - | - | - | -53 | 1,201 | 26,547 | -16,808 | 17,271 | 3,957 |
| Net change in cash and cash equivalents | - | - | - | - | - | - | - | - | 1 | -3,755,894 | 11 | -52,925,461 | 32 | -10,639,704 |
| Right-of-use asset obtained in exchange for operating lease liability | - | - | - | - | - | - | - | - | - | - | 870,373 | - | 139,001 | 42,281 |
| Change in carrying amount of right-of-use asset due to termination of lease | - | - | - | - | - | - | - | - | - | - | - | - | - | 79,229 |
| Income taxes paid | 58,650 | 69,601 | 6,354 | 5,562 | 7,443 | 6,035 | 9,203 | 6,005 | 11,265 | 1,485 | - | - | 3,667 | 5,042 |